Low tumor glutathione level as a sensitivity marker for glutamate-cysteine ligase inhibitors

Satoru Nishizawa, Hideo Araki, Yoshinori Ishikawa, Satoshi Kitazawa, Akito Hata, Tomoyoshi Soga, Takahito Hara

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Previous metabolomic analyses of cancer have revealed elevated glutathione levels in tumors. An inhibitor of cystine uptake was identified to suppress glutathione biosynthesis, leading to ferroptosis, a novel iron-dependent form of cell death that differs from apoptosis and necrosis. Glutamate-cysteine ligase (GCL) is the rate-limiting enzyme in the glutathione biosynthesis pathway. Buthionine sulfoximine (BSO), a GCL inhibitor, has previously demonstrated limited clinical benefits. Therefore, selecting patients who respond well to the inhibitor is a key approach for successful future drug development. Ferroptosis induction by BSO has not been fully examined in prior studies. Therefore, the present study investigated the pharmacological effects of BSO and the association between basal intracellular glutathione levels and sensitivity to BSO in cultured cell lines derived from various types of cancer, including those of the kidney [769P, 786-O, A-498, A704, ACHN, Caki-1, Caki-2, G401, G402, RCC4 VHL(-/-), RCC4 VHL(+/+), SK-NEP-1 and SW156] and ovaries (A2780 and A2780/CDDP). BSO was demonstrated to suppress glutathione levels and induce lipid peroxidation, thereby inhibiting cell viability. The viability-reducing effects of BSO were attenuated by ferroptosis inhibition and enhanced by iron, indicating that BSO induced ferroptosis in cancer cells. The cell lines sensitive to BSO, including G402, tended to exhibit non-significantly lower levels of glutathione compared with the BSO-insensitive cell lines, including Caki-2 (P=0.08). Patient sample data indicated the existence of a population of colorectal tumors with lower glutathione levels compared with those of matched normal tissues that might be suitable for the clinical testing of sensitivity to GCLC inhibitors. Collectively, these data suggest that GCL inhibition leads to ferroptosis in cancer cells, and that low glutathione tumor levels may be a patient selection marker for the use of GCL inhibitors in the treatment of tumors.

Original languageEnglish
Pages (from-to)8735-8743
Number of pages9
JournalOncology Letters
Volume15
Issue number6
DOIs
Publication statusPublished - 2018 Jun 1

Fingerprint

Glutamate-Cysteine Ligase
Buthionine Sulfoximine
Glutathione
Neoplasms
Cell Line
Iron
Metabolomics
Cystine
Patient Selection
Lipid Peroxidation
Colorectal Neoplasms
Ovary
Cultured Cells
Cell Survival
Cell Death
Necrosis
Pharmacology
Apoptosis
Kidney

Keywords

  • Buthionine sulfoximine
  • Cancer
  • Ferroptosis
  • Glutathione
  • Iron

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Nishizawa, S., Araki, H., Ishikawa, Y., Kitazawa, S., Hata, A., Soga, T., & Hara, T. (2018). Low tumor glutathione level as a sensitivity marker for glutamate-cysteine ligase inhibitors. Oncology Letters, 15(6), 8735-8743. https://doi.org/10.3892/ol.2018.8447

Low tumor glutathione level as a sensitivity marker for glutamate-cysteine ligase inhibitors. / Nishizawa, Satoru; Araki, Hideo; Ishikawa, Yoshinori; Kitazawa, Satoshi; Hata, Akito; Soga, Tomoyoshi; Hara, Takahito.

In: Oncology Letters, Vol. 15, No. 6, 01.06.2018, p. 8735-8743.

Research output: Contribution to journalArticle

Nishizawa, S, Araki, H, Ishikawa, Y, Kitazawa, S, Hata, A, Soga, T & Hara, T 2018, 'Low tumor glutathione level as a sensitivity marker for glutamate-cysteine ligase inhibitors', Oncology Letters, vol. 15, no. 6, pp. 8735-8743. https://doi.org/10.3892/ol.2018.8447
Nishizawa, Satoru ; Araki, Hideo ; Ishikawa, Yoshinori ; Kitazawa, Satoshi ; Hata, Akito ; Soga, Tomoyoshi ; Hara, Takahito. / Low tumor glutathione level as a sensitivity marker for glutamate-cysteine ligase inhibitors. In: Oncology Letters. 2018 ; Vol. 15, No. 6. pp. 8735-8743.
@article{abbef652d5c34933a75cd390b1bd8f57,
title = "Low tumor glutathione level as a sensitivity marker for glutamate-cysteine ligase inhibitors",
abstract = "Previous metabolomic analyses of cancer have revealed elevated glutathione levels in tumors. An inhibitor of cystine uptake was identified to suppress glutathione biosynthesis, leading to ferroptosis, a novel iron-dependent form of cell death that differs from apoptosis and necrosis. Glutamate-cysteine ligase (GCL) is the rate-limiting enzyme in the glutathione biosynthesis pathway. Buthionine sulfoximine (BSO), a GCL inhibitor, has previously demonstrated limited clinical benefits. Therefore, selecting patients who respond well to the inhibitor is a key approach for successful future drug development. Ferroptosis induction by BSO has not been fully examined in prior studies. Therefore, the present study investigated the pharmacological effects of BSO and the association between basal intracellular glutathione levels and sensitivity to BSO in cultured cell lines derived from various types of cancer, including those of the kidney [769P, 786-O, A-498, A704, ACHN, Caki-1, Caki-2, G401, G402, RCC4 VHL(-/-), RCC4 VHL(+/+), SK-NEP-1 and SW156] and ovaries (A2780 and A2780/CDDP). BSO was demonstrated to suppress glutathione levels and induce lipid peroxidation, thereby inhibiting cell viability. The viability-reducing effects of BSO were attenuated by ferroptosis inhibition and enhanced by iron, indicating that BSO induced ferroptosis in cancer cells. The cell lines sensitive to BSO, including G402, tended to exhibit non-significantly lower levels of glutathione compared with the BSO-insensitive cell lines, including Caki-2 (P=0.08). Patient sample data indicated the existence of a population of colorectal tumors with lower glutathione levels compared with those of matched normal tissues that might be suitable for the clinical testing of sensitivity to GCLC inhibitors. Collectively, these data suggest that GCL inhibition leads to ferroptosis in cancer cells, and that low glutathione tumor levels may be a patient selection marker for the use of GCL inhibitors in the treatment of tumors.",
keywords = "Buthionine sulfoximine, Cancer, Ferroptosis, Glutathione, Iron",
author = "Satoru Nishizawa and Hideo Araki and Yoshinori Ishikawa and Satoshi Kitazawa and Akito Hata and Tomoyoshi Soga and Takahito Hara",
year = "2018",
month = "6",
day = "1",
doi = "10.3892/ol.2018.8447",
language = "English",
volume = "15",
pages = "8735--8743",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "6",

}

TY - JOUR

T1 - Low tumor glutathione level as a sensitivity marker for glutamate-cysteine ligase inhibitors

AU - Nishizawa, Satoru

AU - Araki, Hideo

AU - Ishikawa, Yoshinori

AU - Kitazawa, Satoshi

AU - Hata, Akito

AU - Soga, Tomoyoshi

AU - Hara, Takahito

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Previous metabolomic analyses of cancer have revealed elevated glutathione levels in tumors. An inhibitor of cystine uptake was identified to suppress glutathione biosynthesis, leading to ferroptosis, a novel iron-dependent form of cell death that differs from apoptosis and necrosis. Glutamate-cysteine ligase (GCL) is the rate-limiting enzyme in the glutathione biosynthesis pathway. Buthionine sulfoximine (BSO), a GCL inhibitor, has previously demonstrated limited clinical benefits. Therefore, selecting patients who respond well to the inhibitor is a key approach for successful future drug development. Ferroptosis induction by BSO has not been fully examined in prior studies. Therefore, the present study investigated the pharmacological effects of BSO and the association between basal intracellular glutathione levels and sensitivity to BSO in cultured cell lines derived from various types of cancer, including those of the kidney [769P, 786-O, A-498, A704, ACHN, Caki-1, Caki-2, G401, G402, RCC4 VHL(-/-), RCC4 VHL(+/+), SK-NEP-1 and SW156] and ovaries (A2780 and A2780/CDDP). BSO was demonstrated to suppress glutathione levels and induce lipid peroxidation, thereby inhibiting cell viability. The viability-reducing effects of BSO were attenuated by ferroptosis inhibition and enhanced by iron, indicating that BSO induced ferroptosis in cancer cells. The cell lines sensitive to BSO, including G402, tended to exhibit non-significantly lower levels of glutathione compared with the BSO-insensitive cell lines, including Caki-2 (P=0.08). Patient sample data indicated the existence of a population of colorectal tumors with lower glutathione levels compared with those of matched normal tissues that might be suitable for the clinical testing of sensitivity to GCLC inhibitors. Collectively, these data suggest that GCL inhibition leads to ferroptosis in cancer cells, and that low glutathione tumor levels may be a patient selection marker for the use of GCL inhibitors in the treatment of tumors.

AB - Previous metabolomic analyses of cancer have revealed elevated glutathione levels in tumors. An inhibitor of cystine uptake was identified to suppress glutathione biosynthesis, leading to ferroptosis, a novel iron-dependent form of cell death that differs from apoptosis and necrosis. Glutamate-cysteine ligase (GCL) is the rate-limiting enzyme in the glutathione biosynthesis pathway. Buthionine sulfoximine (BSO), a GCL inhibitor, has previously demonstrated limited clinical benefits. Therefore, selecting patients who respond well to the inhibitor is a key approach for successful future drug development. Ferroptosis induction by BSO has not been fully examined in prior studies. Therefore, the present study investigated the pharmacological effects of BSO and the association between basal intracellular glutathione levels and sensitivity to BSO in cultured cell lines derived from various types of cancer, including those of the kidney [769P, 786-O, A-498, A704, ACHN, Caki-1, Caki-2, G401, G402, RCC4 VHL(-/-), RCC4 VHL(+/+), SK-NEP-1 and SW156] and ovaries (A2780 and A2780/CDDP). BSO was demonstrated to suppress glutathione levels and induce lipid peroxidation, thereby inhibiting cell viability. The viability-reducing effects of BSO were attenuated by ferroptosis inhibition and enhanced by iron, indicating that BSO induced ferroptosis in cancer cells. The cell lines sensitive to BSO, including G402, tended to exhibit non-significantly lower levels of glutathione compared with the BSO-insensitive cell lines, including Caki-2 (P=0.08). Patient sample data indicated the existence of a population of colorectal tumors with lower glutathione levels compared with those of matched normal tissues that might be suitable for the clinical testing of sensitivity to GCLC inhibitors. Collectively, these data suggest that GCL inhibition leads to ferroptosis in cancer cells, and that low glutathione tumor levels may be a patient selection marker for the use of GCL inhibitors in the treatment of tumors.

KW - Buthionine sulfoximine

KW - Cancer

KW - Ferroptosis

KW - Glutathione

KW - Iron

UR - http://www.scopus.com/inward/record.url?scp=85046452466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046452466&partnerID=8YFLogxK

U2 - 10.3892/ol.2018.8447

DO - 10.3892/ol.2018.8447

M3 - Article

VL - 15

SP - 8735

EP - 8743

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 6

ER -